Canopy Growth Stock Declines as Investor Caution Persists

Share Price Weakness Continues Multi-Year Trend

Canopy Growth's stock has now traded below $1 per share for extended periods, triggering Nasdaq delisting concerns and forcing the company to consider a reverse split. The decline reflects broader sector headwinds: oversupply in Canada, slow U.S. federal reform, and tightening capital markets for unprofitable cannabis operators.

Market cap now sits below $500 million. That's down from a peak of more than $15 billion in 2018 when Constellation Brands invested $4 billion for a 38% stake. The investment is now underwater by more than 90%.

The Bull Case Remains Thin

Optimists point to Canopy's brand portfolio, U.S. optionality through Canopy USA, and potential for cost restructuring to stabilize cash flow. Management has cut headcount by more than 50% since 2022 and exited unprofitable international markets.

But the bull case hinges on two low-probability catalysts: federal U.S. legalization (which remains stalled in Congress) and a dramatic turnaround in Canadian recreational margins, where provincial pricing pressure continues.

Cash Burn and Covenant Risk

Canopy burned approximately $150 million in cash during its most recent fiscal quarter, according to its latest 10-Q filing. Roughly $200 million in cash and equivalents sits on the balance sheet, giving the company fewer than two quarters of runway at the current burn rate.

Debt covenants tied to Canopy's senior secured notes require minimum liquidity thresholds, and a breach would trigger acceleration clauses that could force asset sales or a distressed restructuring.

Management has signaled it's exploring strategic alternatives, including asset sales and partnerships. No concrete deals have materialized.

Comparable-Company Multiples Offer No Support

Canopy trades at roughly 0.3x trailing revenue, a discount to U.S. MSOs like Curaleaf (0.5x) and Trulieve (0.6x), but those operators are EBITDA-positive and don't face the same liquidity constraints. Canadian peers Aurora Cannabis and Tilray Brands trade at similar multiples but have stabilized cash flow.

The valuation gap reflects execution risk. Revenue has declined year-over-year for five consecutive quarters.

U.S. Optionality Remains Theoretical

Canopy USA—the company's U.S. holding structure for Wana Brands, Jetty Extracts, and Acreage Holdings—can't consolidate financials until federal legalization occurs. That structure gives Canopy a call option on U.S. upside. It doesn't generate cash today.

Acreage, in particular, has struggled. Limited state footprint. Intense competition. Store-level EBITDA has compressed as New York and other Eastern markets open.

What to Watch

The next catalyst is Canopy's Q4 fiscal 2026 earnings, expected in early June. Investors will focus on three metrics: quarterly cash burn, liquidity runway, and any update on strategic alternatives.

If burn remains above $100 million per quarter and no asset-sale announcement materializes, the stock likely tests new lows. A reverse split would reset the share price mechanically but wouldn't change the underlying fundamentals. For a detailed breakdown of Canopy's capital structure and competitive positioning, see the CannIntel topic hub on Canopy Growth stock.